Kardigan IPO Pricing: $400 Million Raised at $16 a Share

Key takeaways

• Kardigan, Inc. set its IPO pricing at $16.00 per share, selling 25 million shares for $400 million in gross proceeds, according to its 424B4 prospectus filed June 18, 2026.
• Proceeds to the company before expenses were $372 million after a $1.12 per share underwriting discount.
• The stock was set to list on the Nasdaq Global Market under the ticker KARD.
• The company reserved about 5% of the shares for directors, officers and employees through a directed share program.
• Net loss reached $191.9 million in 2025, and cash and short-term investments totaled $287.1 million at March 31, 2026.

The IPO pricing terms

Kardigan describes itself as a clinical-stage precision therapeutics company targeting the root causes of specific cardiovascular diseases. Its prospectus, dated June 17, 2026, states that there was no public market for its stock before the offering.

Item	Per share	Total
IPO price	$16.00	$400,000,000
Underwriting discount	$1.12	$28,000,000
Proceeds to Kardigan, before expenses	$14.88	$372,000,000

The underwriters also received a 30-day option to buy up to 3,750,000 additional shares. J.P. Morgan, Jefferies, Leerink Partners and TD Cowen led the offering. The spread, 7% of the offering price, is the conventional rate for biotech IPOs.

IPO valuation at the offering price

The prospectus lists 89,339,121 shares outstanding after the offering, or 93,089,121 if the underwriters’ option is fully exercised. At $16, that implies a market capitalization of about $1.43 billion before any option exercise, by our calculation from the filing.

Pro forma cash offers a useful benchmark. Adding the $287.1 million in cash, cash equivalents and short-term investments at March 31, 2026, to the estimated net proceeds of about $366.8 million gives roughly $654 million, before spending after March 31. On that basis, cash would account for a little under half of the implied market value, with the remainder representing what investors assigned to the pipeline.

The pipeline behind the price

The prospectus describes three clinical programs:

• Danicamtiv, for genetic dilated cardiomyopathy, in Phase 2b/3.
• Ataciguat, for calcific aortic valve stenosis, in Phase 2b.
• Tonlamarsen, for acute severe hypertension, in Phase 2.

Having three mid-to-late stage programs spreads risk more than a single-asset company would, though all three target cardiovascular disease. Net proceeds are earmarked for clinical development of the three programs, research activities, and working capital and general corporate purposes.

Losses are climbing

The financial data show spending accelerating as programs advance:

• First quarter 2026: net loss of $56.1 million, compared with $18.0 million a year earlier.
• 2025: net loss of $191.9 million, up from $88.7 million in 2024.

If the first-quarter pace held for the rest of 2026, annual losses would exceed $220 million, our simple extrapolation rather than company guidance. That spending rate is why the size of the raise matters: the IPO proceeds plus existing cash provide a multi-year runway at the disclosed burn, depending on how trial costs evolve.

The directed share program

Reserving about 1.25 million shares for insiders and employees at the IPO price is common, and it lets people close to the company participate on the same terms as public buyers. A directed allocation does not by itself commit anyone to buy, so the filing should not be read as a measure of insider demand.

What to watch

Watch for data readouts from the danicamtiv Phase 2b/3 study, which is the most advanced program, progress in the ataciguat and tonlamarsen trials, whether the underwriters exercise their 3.75 million share option, and quarterly cash burn relative to the first-quarter 2026 level.